Related Experiment Videos
HRT and heart disease: problems and prospects.
Angela H E M Maas1, Yolanda van der Graaf, Yvonne T van der Schouw
1Department of Cardiology, Isala Klinieken, P.O. Box 10400, 8000 GK Zwolle, The Netherlands. a.maas@diagram-zwolle.nl
Maturitas
|April 6, 2004
Summary
Hormone replacement therapy (HRT) is safe long-term after menopause but risky if started after a cardiovascular event. Timing is crucial for HRT
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Women's Health
Background:
- Observational and randomized clinical studies show conflicting results regarding hormone replacement therapy (HRT) safety.
- Cardiovascular disease (CVD) risk is a significant concern for postmenopausal women.
Purpose of the Study:
- To reconcile divergent findings on HRT's cardiovascular effects.
- To elucidate the impact of HRT timing on cardiovascular outcomes.
Main Methods:
- Review and synthesis of existing observational and randomized clinical trial data on HRT and cardiovascular events.
- Analysis of factors influencing HRT's vascular effects, including menopausal status and pre-existing cardiovascular disease.
Main Results:
- Chronic HRT use initiated long after menopause shows no adverse effect on coronary heart disease (CHD) event rates.
- Initiating HRT shortly after a cardiovascular event increases early recurrent CHD events.
- HRT in the presence of endothelial dysfunction and atherosclerosis promotes plaque instability, inflammation, and prothrombotic effects.
Conclusions:
- The timing of HRT initiation relative to menopause is critical for its vascular safety and effectiveness.
- HRT's cardiovascular impact is dependent on the underlying vascular health of the individual.